NCT04704531View on ClinicalTrials.gov

Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.

PHASE2CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

June 8, 2022

Study Completion Date

June 8, 2022

Conditions
Dry Eye
Interventions
DRUG

Sodium Hyaluronate Ophthalmic 0.4% BID

Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.

DRUG

Sodium Hyaluronate Ophthalmic 0.4% QID

Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.

DRUG

Sodium Hyaluronate Ophthalmic 0.4% Six times per day

Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.

Trial Locations (1)

44670

Instituto Jalisciense del Metabolismo, S.C., Guadalajara

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY

NCT04704531 - Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease. | Biotech Hunter | Biotech Hunter